Elanco Animal Health Incorporated (NYSE:ELAN) Receives $18.29 Average PT from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $18.00.

A number of research firms have weighed in on ELAN. Piper Sandler reiterated a “neutral” rating and issued a $19.00 price target (up from $18.00) on shares of Elanco Animal Health in a research report on Monday, May 13th. Barclays cut their price target on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday.

Elanco Animal Health Stock Up 1.1 %

ELAN opened at $14.43 on Monday. The firm’s 50 day simple moving average is $16.43 and its two-hundred day simple moving average is $15.71. The company has a market capitalization of $7.13 billion, a PE ratio of -5.45, a PEG ratio of 1.40 and a beta of 1.45. Elanco Animal Health has a 1-year low of $8.52 and a 1-year high of $18.80. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.95.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.08. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the prior year, the business posted $0.45 earnings per share. The business’s quarterly revenue was down 4.1% on a year-over-year basis. As a group, equities analysts forecast that Elanco Animal Health will post 0.93 EPS for the current year.

Insider Transactions at Elanco Animal Health

In other news, Director William F. Doyle purchased 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was bought at an average cost of $16.98 per share, with a total value of $254,700.00. Following the completion of the purchase, the director now owns 76,330 shares in the company, valued at $1,296,083.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.57% of the company’s stock.

Institutional Trading of Elanco Animal Health

A number of large investors have recently made changes to their positions in ELAN. SG Capital Management LLC purchased a new position in Elanco Animal Health in the first quarter worth about $4,211,000. Cetera Advisors LLC purchased a new position in shares of Elanco Animal Health in the 1st quarter worth approximately $213,000. Comerica Bank increased its position in shares of Elanco Animal Health by 272.6% during the 1st quarter. Comerica Bank now owns 11,716 shares of the company’s stock valued at $191,000 after purchasing an additional 8,572 shares during the last quarter. Tidal Investments LLC lifted its position in Elanco Animal Health by 34.6% in the first quarter. Tidal Investments LLC now owns 22,575 shares of the company’s stock worth $368,000 after buying an additional 5,797 shares during the last quarter. Finally, Redwood Investment Management LLC bought a new stake in Elanco Animal Health in the first quarter worth $1,512,000. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.